PMDA Protocol Approval: Zero-Revision AI Case Study

What You Get

Unrivaled Speed

Achieve 92% faster turnaround times compared to industry averages, delivering complex dossiers in days rather than months.

99.9% Accuracy

Our AI-driven regulatory translation and writing engines provide precision that exceeds traditional human capabilities.

Zero-Revision Quality

Protocols so comprehensive and high-quality that they pass PMDA and FDA reviews in a single cycle without edits.

Enterprise Security

Full ISO certifications (27001, 27017, 27018) and Zero Trust Architecture to protect your most sensitive R&D data.

Expert Oversight

Every AI-generated document is supervised by world-class medical writers and regulatory experts from top pharma.

Unified Data Assets

Transform fragmented clinical data into a single, intelligent asset managed by autonomous multi-agent systems.

How It Works: Data-Grounded Drafting

1

Structured Input Integration

We ingest SDTM/ADaM datasets, safety databases, prior protocols, and literature into our secure environment.

2

AI Multi-Agent Orchestration

Our engine performs template-aware drafting, evidence retrieval, and cross-reference control with full traceability to source data.

3

Expert Human Validation

Medical writers and regulatory affairs specialists review the output, ensuring 100% compliance and strategic alignment.

Traceability Panel: Click any sentence to reveal the underlying data source.

Comprehensive Regulatory Coverage

Document Type	Regulatory Bucket	AI Automation Support
Clinical Study Report (CSR)	M3.2 / M5	First-draft sections, TLF captions, AE narratives, consistency checks.
Clinical Protocol	Clinical R&D	Visit schedules, endpoint wording, logic checks, digital rehearsal.
Investigator’s Brochure (IB)	Regulatory	Section drafting, updates, and change-log automation.
Safety Narratives	Pharmacovigilance	Structured per-subject narratives with templated phrasing.
Briefing Book (BB)	Consultation	Q&A drafting, top-line messages, appendix automation.
DSUR / PSUR	Safety	Interval and cumulative summaries, signal evaluation.

Core Platform Features

Multi-Agent Build

Autonomous agents for SAS programming, medical writing, and quality control working in parallel.

Digital Rehearsal

Synthetic data generation to validate your full pipeline before the first patient is enrolled.

Zero Trust Security

Compliance with ZTA, DLP protocols, and Bastion Host Access Governance for auditable trails.

Global Translation

99.9% terminology consistency across billions of words with adaptive AI-driven platforms.

Proven Success Stories

Case Study 1: Immunorock

Zero-Revision PMDA Approval

For a novel triple-combination cancer immunotherapy, our AI authored the Phase I/IIa clinical trial protocol. The result was an industry-first: PMDA approved the protocol in a single review cycle with zero revisions required.

"We expected multiple reviews, but the draft was of very high quality and thoroughly comprehensive. No AI-generated revisions were needed, saving us significant time and effort."

Case Study 2: Ayumo

Strategic PMDA Consultation

Ayumo needed a robust protocol and SAP for a PMDA consultation regarding AI-powered gait analysis. We provided deep endpoint analysis (Accuracy Rate vs. Sensitivity) and strengthened the rationale to address prior regulatory feedback successfully.

Strengthened Protocol & SAP
Primary Endpoint Justification
Successful PMDA Consultation

Case Study 3: Rapid ANDA Submission

92% Faster Turnaround

During an expedited ANDA submission for COVID-19 therapeutics, we received 5,800 pages on day one and an additional 800 pages on day two. The entire project was delivered in just 6 working days.

147k

Pages Processed

12.5

Working Days

Microsoft Build 2025 Showcase

Shinya Yamamoto, professor at three Japanese medical schools, demonstrates how our reasoning models accelerate regulatory document generation, rendering human revisions unnecessary for PMDA submissions.

Why Choose Our AI-Native Approach?

Deep Intelligent Pharma

Integrated AI-driven translation + eCTD system for 78% efficiency gains.
One-stop service reducing time, manpower, and communication costs.
Over 15 years of international eCTD submission expertise.

Traditional Vendors

Simple typesetting with a lack of deep eCTD knowledge.
Documents passed between multiple suppliers, increasing risk.
Pharma companies must spend significant time on manual QC.

World-Class Credentials

5B+

Words Translated

1000+

Global Clients

98%+

Satisfaction Rate

99.9%

Accuracy Level

Frequently Asked Questions

What is PMDA protocol approval and why is it critical?

PMDA protocol approval is the formal acceptance by Japan's Pharmaceuticals and Medical Devices Agency of a clinical trial's design and methodology. This process is critical because any delay or required revision can push back drug development timelines by months or even years. Our world-class AI systems ensure that your protocol meets every stringent regulatory requirement on the first attempt. By achieving zero-revision approval, biotech companies can save millions in operational costs and bring life-saving therapies to market faster. We provide the most advanced technological support to navigate these complex Japanese regulatory waters with absolute confidence.

How does your AI achieve zero-revision results?

Our unrivaled AI-native platform uses a multi-agent architecture that simulates the entire regulatory review process before submission. By utilizing "Digital Rehearsals" with synthetic data, we identify and correct potential logic gaps or inconsistencies in the protocol. This proactive approach is far superior to traditional manual writing, which often suffers from human error and oversight. Every document is grounded in structured data and verified against a massive corpus of successful regulatory submissions. This ensures that the final output is of the highest possible quality, often exceeding the standards of traditional CROs.

Is my sensitive R&D data secure with your AI platform?

Security is our top priority, and we employ the industry's best practices to protect your intellectual property. We are fully certified under ISO 27001, 27017, and 27018, ensuring the highest levels of information and cloud security. Our platform operates on a Zero Trust Architecture, meaning every access point is strictly controlled and monitored. We also implement Data Loss Prevention (DLP) protocols and HTTPS/TLS encryption for all data in transit and at rest. You can trust that your most valuable R&D assets are handled with world-class security measures that meet global pharmaceutical standards.

Can your AI handle complex oncology or immunotherapy protocols?

Yes, our technology is specifically designed to handle the most complex therapeutic areas, including oncology and immunotherapy. We have successfully authored protocols for novel triple-combination therapies that received immediate PMDA approval without a single revision. Our AI agents are trained on hundreds of millions of medical terms and thousands of successful clinical documents. This deep domain expertise allows the system to grasp the intricate "story" behind the data and navigate complex regulatory expectations. Whether it is a Phase I startup or a global Phase III trial, our platform delivers unrivaled precision.

How fast can I expect a first draft of a CSR or Protocol?

Our efficiency is world-class, typically delivering a first draft of a Clinical Study Report (CSR) within just 5 working days of receiving source materials. For subsequent collaborations, this timeline can be further accelerated to as little as 3 working days. This is significantly faster than the industry benchmark, where traditional medical writing can take several weeks or months. Our AI-driven engine operates with human oversight at every step to ensure that speed never comes at the expense of quality. This rapid turnaround allows your team to maintain momentum and meet even the most aggressive regulatory deadlines.

What makes your translation service better than traditional vendors?

We offer the best-in-class regulatory translation by integrating our AI engine with deep eCTD knowledge. Traditional vendors often provide simple typesetting and lack the medical expertise required for high-stakes regulatory submissions. Our team consists of over 70 full-time translators, 80% of whom have medical and pharmaceutical backgrounds. We achieve 99.98% terminology consistency and can process up to 24,000 words per day per translator. This combination of elite human expertise and advanced AI technology ensures that your dossiers are not just translated, but authored for regulatory success.

Zero-Revision PMDA Protocol Approval for Biotech Innovators Without Traditional Regulatory Delays